One Biomass Stream, Multiple Revenue Lines
The biorefinery concept is simple to state and genuinely difficult to execute: grow one batch of algae, then extract every useful compound from it before discarding the residue. The appeal is obvious. Algae biomass costs roughly $1–10/kg to produce depending on system type. If that kilogram contains 5% astaxanthin-equivalent pigments, 30–50% protein, and 10–20% lipids, treating it as a single-product input is economically wasteful — and often the difference between a viable unit economics model and one that doesn't close.
The concept borrows from petroleum refining — crude oil enters one end, a cascade of products (fuel, lubricants, plastics, waxes) exits the other. For algae, the analogy is instructive but imperfect. Petroleum products are fungible commodities with global spot prices. Algae products often require individual regulatory approval, different downstream customers, different packaging, and different sales cycles. The biorefinery model improves the economics on paper; making it work operationally requires solving several problems simultaneously.
This module covers what a functional algae biorefinery actually involves: how cascade extraction is designed, which product combinations work, which don't, and what the economics look like when you run the numbers honestly rather than optimistically.
How to Structure the Cascade
Not all biorefineries are designed the same way. The architecture — which products are extracted, in which order, using which methods — determines capital cost, operational complexity, and product quality. Three broad structures dominate discussion in the literature, and each involves a different trade-off between simplicity and yield.
The choice of architecture is driven by the target product mix and strain biology, not by a generic preference for one approach. A Haematococcus facility optimised for astaxanthin will use a sequential cascade starting with SC-CO₂; a Spirulina facility targeting protein with a minor lipid stream will typically use an integrated wet process. They are not interchangeable.
The first product extracted determines the architecture of everything downstream. Choose the extraction method for your highest-value product first; then engineer the residue stream to recover the next-highest value product from whatever is left.
A practical constraint almost never discussed in introductory texts: the order of extraction is constrained by chemistry. Lipid extraction with organic solvents will denature proteins. Alkaline conditions for protein extraction will degrade heat-sensitive pigments. SC-CO₂ for pigments leaves a protein-rich residue that can be processed further without contamination. This is why SC-CO₂ → protein → carbohydrate/residue is the most common cascade sequence in the literature — not because it is the obvious choice, but because it is chemically compatible.
What You Actually Get — and What It's Worth
The biorefinery model requires you to know, for each product in the cascade: what yield is realistic at commercial scale, what quality specification buyers require, and what the market price is. All three are often worse than the theoretical maximums quoted in early-stage pitch materials.
Extracted first because it is the highest-value product and SC-CO₂ leaves the biomass intact for further processing. Realistic yield from Haematococcus: 1.5–2.5% of dry biomass under optimised stress induction. Quality specifications for nutraceuticals require ≥5% astaxanthin in the extract and documentation of natural origin.
DHA-rich oil from Schizochytrium or Thraustochytrid strains extracted early in cascade — often step 1 in heterotrophic biorefinery models. Oil yield 40–50% DW in optimised Schizochytrium, but significantly lower in Nannochloropsis (15–25%). Food-grade purity requires additional refining; the per-kg price is far lower than pigments, so volume matters enormously.
Extracted from the lipid-depleted residue using alkaline conditions (pH 9–11) followed by isoelectric precipitation. Yield 60–75% of total protein content, but functional properties (solubility, emulsification) are often reduced compared to whole-cell protein. The $5–12/kg market price means this is only profitable if extraction cost per kg is below ~$3. Rarely viable as a standalone product from high-cost PBR biomass.
The carbohydrate fraction of the post-protein residue has limited commercial value unless the strain produces a high-value polysaccharide (spirulina's phycocyanin is a pigment-protein, but some green algae produce bioactive beta-glucans worth $20–50/kg). In most cascades, the carbohydrate residue is best used for anaerobic digestion to biogas — recovering energy rather than generating a saleable product.
Phycocyanin is the exception to the "pigment first" rule about SC-CO₂: it is a water-soluble protein-pigment complex, not a lipid-soluble carotenoid. It is extracted first using cold aqueous buffer because it is heat-labile and would be destroyed by organic solvent extraction. Food-grade phycocyanin requires ≥0.4 absorbance ratio (A620/A280); pharmaceutical grade requires ≥4.0. This quality gap represents a 5–10× price difference.
The Execution Gap
The biorefinery model consistently underperforms its economic projections in practice. Understanding why is more useful than the concept itself. There are five recurring failure modes, each operating independently but often appearing together.
Simultaneous market demand is not guaranteed
A three-product cascade requires three buyers with simultaneous demand and simultaneous specifications. If the pigment market is oversupplied and prices are soft, the entire cascade economics change — the protein revenue needs to compensate, but protein buyers require consistent supply on their terms. Coordinating three separate revenue streams is not a theoretical problem; it is a daily sales and operations problem that kills startups.
Extraction step interactions degrade product quality
The neat sequential cascade in diagrams assumes each extraction step leaves the downstream fraction intact. In practice, the mechanical stress of cell disruption prior to SC-CO₂ can oxidise sensitive lipids; solvent residues in the protein fraction require additional purification to meet food-grade specifications; alkaline protein extraction degrades polysaccharide bioactivity. Each compromise reduces the achievable price for subsequent products.
Regulatory approval pathways are product-specific
The protein fraction, lipid fraction, and pigment fraction from the same biomass batch each require separate regulatory approval in most jurisdictions — FSSAI novel food notification, EFSA health claim approval, or FDA GRAS status are not transferable between fractions. A startup commercialising three products from one biorefinery may need to run three regulatory processes in parallel, each taking 2–5 years and costing $200,000–$2 million in compliance spend.
Capital requirements scale faster than revenue
Each additional extraction step requires capital equipment. A SC-CO₂ unit at 50L/batch capacity costs $300,000–$800,000. Adding a protein extraction module adds $150,000–$400,000. Anaerobic digestion adds $100,000–$300,000. The total CapEx for a fully integrated small-scale biorefinery is often $1–3 million before any cultivation infrastructure — and at small scale, the per-kg capital depreciation cost is prohibitive.
Yield assumptions overstate commercial reality
Published TEA models for biorefineries routinely use laboratory-maximum yields for each product. At commercial scale, astaxanthin yields are 60–80% of lab maximums due to outdoor stress-induction variability; protein extraction yields are 65–75% due to incomplete cell disruption and precipitation losses; SC-CO₂ extraction efficiency drops at high throughput. A realistic TEA that applies 70% of theoretical yield across three cascaded steps quickly demonstrates why the economics are tighter than they appear.
When Biorefinery Economics Do Work
| Biorefinery Case | Primary Product | Co-Product(s) | Commercial Status | Viability Verdict |
|---|---|---|---|---|
| Spirulina (phycocyanin + biomass) | Phycocyanin — $100–500/kg food grade | Dried biomass supplement ($12–20/kg) | Proven at scale globally; Indian producers running commercially | Validated |
| Schizochytrium DHA (oil + protein) | DHA oil — $15–50/kg | Protein meal for aquafeed ($4–7/kg) | Commercial — Corbion, DSM-Firmenich, Evonik running at scale | Validated |
| Haematococcus (astaxanthin + protein) | Astaxanthin — $2,000–4,500/kg | Protein residue, carbohydrate fraction | Pilot-scale demonstrated (Algatech, Cyanotech); protein co-product rarely commercialised | Partial |
| Nannochloropsis (EPA + protein) | EPA oil — $20–60/kg | Protein concentrate, carotenoids | Pilot-scale TEAs published; full commercial cascade not yet demonstrated | Pre-commercial |
| Chlorella (protein + lutein + chlorophyll) | Protein — $8–15/kg | Lutein ($1,000–2,000/kg), chlorophyll | Lutein extraction from Chlorella is commercial in Japan and Taiwan; integrated cascade is emerging | Emerging |
| Tetraselmis / mixed culture (biogas + biofuel + protein) | Protein / biomass — $3–6/kg | Biogas energy recovery | Demonstrated in wastewater treatment applications; not commercially viable as primary revenue model | Not viable standalone |
This is not a pessimistic statement — it is a design principle. The cascade is real and adds value. But a business plan that requires three products to find markets simultaneously, pass regulatory approval simultaneously, and achieve planned yields simultaneously is not a business plan. It is optimism organised into a spreadsheet. The right approach: prove the primary product commercially, then add co-product revenue as it becomes available.
First, hexane residues in the biomass after astaxanthin extraction will contaminate the protein fraction. Removing hexane to below food-safety limits (typically <1 mg/kg in finished protein) requires a solvent stripping step — energy-intensive and potentially heat-damaging to the protein structure. If the protein fraction is destined for human food applications, this is likely to create regulatory complications under FSSAI food safety standards. If it is for animal feed, the limit is more generous, but buyers may still reject hexane-treated product.
Second, hexane denatures protein. The alkaline protein extraction step that follows will achieve significantly lower yield (potentially 30–40% lower than from SC-CO₂-treated residue) because hexane has cross-linked some protein structures and made them insoluble. The protein quality will also be degraded — functional properties like solubility and emulsification will be reduced, which limits the price achievable for the protein product.
The correct approach is SC-CO₂ extraction for astaxanthin as step 1. Yes, a 50L SC-CO₂ unit costs $300,000–$800,000 versus $50,000–$150,000 for hexane equipment. But SC-CO₂ leaves a clean, solvent-free residue with intact protein structure. The protein fraction from SC-CO₂-treated Haematococcus residue has achieved 65–75% extraction yield in lab studies and meets food-grade specifications without additional solvent removal steps. The CapEx premium is justified by the multi-product cascade economics — if astaxanthin is fetching $2,000–4,500/kg, even a modest protein co-product revenue at $6–10/kg significantly improves the overall facility economics. The facility that cuts corners on the first extraction method typically makes all subsequent cascade steps less valuable.
On EPA oil at $30/kg: What is the assumed extraction yield from Nannochloropsis biomass? Literature reports 15–25% DW lipid content with EPA representing 30–40% of total lipids — meaning EPA yield is approximately 4–10% of dry biomass. At what purity? Food-grade EPA requires >90% EPA in total fatty acids, which requires additional molecular distillation adding $2–5/kg cost. Who is the buyer and at what volume? EPA at $30/kg competes with fish-oil-derived EPA at $8–15/kg — the algal premium requires certification of sustainability origin (MSC-equivalent for algae does not yet have a universal standard). Has EPA been approved for the target application under FSSAI or the relevant jurisdiction?
On protein concentrate at $8/kg: What is the specification the buyer requires? Food-grade protein concentrate from lipid-depleted Nannochloropsis biomass has limited published data on functional properties. Amino acid profile is complete but DIAAS scores are not widely published for this strain. $8/kg is achievable only if the protein extraction yield is >65% and the product meets buyer specifications without additional processing. What is the extraction cost per kg? If alkaline extraction costs $3–4/kg at this scale, the margin is too thin to justify the capital investment.
On carbon credits at $15/tonne: This is the most questionable revenue line. No verified methodology currently exists for issuing voluntary carbon credits against microalgae biomass production in a way that auditors will certify at scale. The $15/tonne assumes a credit is issuable and verifiable — which has not been demonstrated for any algae production facility globally. This revenue line should be removed from any Year 1–5 model and treated as potential upside contingent on methodology development.
The Year 3 profitability claim almost certainly depends on all three revenue lines performing simultaneously and at planned yields. Ask the modeller to run a sensitivity analysis where (a) EPA yield is 60% of projected, (b) protein revenue is removed entirely, and (c) carbon credits are zero. If the model does not survive that stress test, Year 3 profitability is an artefact of optimistic assumptions, not a credible projection.
First, the extraction chemistry is simple. Phycocyanin is water-soluble and cold-stable — it is extracted by mixing biomass paste with cold aqueous buffer, centrifuging off the cell debris, and freeze-drying the supernatant. No organic solvents. No SC-CO₂ equipment. No high-pressure systems. The capital cost of a phycocyanin extraction line is $50,000–$200,000 for a pilot-scale operation — accessible to small Indian producers. The cell debris retains sufficient protein and nutritional value to sell as dried biomass supplement or animal feed at $12–20/kg without additional processing.
Second, the two products do not compete for the same cellular fraction. Phycocyanin is a protein-pigment in the cytoplasm; the remaining biomass contains the structural protein, carbohydrates, and remaining cellular material. Extracting phycocyanin does not meaningfully deplete the protein or nutritional value of the dried biomass residue. This makes the cascade chemically compatible without the quality degradation seen in solvent-cascade systems.
Third — and most importantly — both products have established markets with understood buyer specifications. Food-grade phycocyanin for the natural food colouring market (replacing synthetic Blue 1) has buyers in Europe (E spirulina is approved as a food colour under EU Regulation 1333/2008), the US, and Japan. Spirulina dried biomass supplement has been sold in India since the 1980s and has FSSAI approval. This means a Spirulina producer does not need to develop new markets — they are selling into existing demand.
The per-kg economics look modest compared to astaxanthin because phycocyanin food grade trades at $100–500/kg, not $2,000–4,500/kg. But the capital required, the operational complexity, and the market development cost are all dramatically lower. Indian Spirulina producers in Tamil Nadu and Gujarat are running this model profitably at $5–15/kg whole biomass production cost, which is the fundamental proof that it works.
Solazyme (founded 2003, pivoted 2016, renamed TerVia): Solazyme built a heterotrophic algae fermentation platform that was originally positioned as a biofuel biorefinery — algae oil for fuel, with protein co-products. The biofuel application collapsed when oil prices fell from $100+/barrel in 2014 to $30–50/barrel in 2015–2016, making any algal biofuel economically non-viable at any realistic scale. The pivot to specialty food oils (Thrive Algae Oil) and cosmetic ingredients under TerVia was an attempt to use the same fermentation infrastructure to produce higher-value products. TerVia was eventually acquired by Corbion in 2017. The failure mode was not technical — Solazyme's fermentation technology worked. It was economic: the primary revenue stream (biofuel) was priced out of the market by commodity petroleum, and the biorefinery had been capitalised and scaled on the assumption that the fuel market would remain viable.
Aurora Algae (founded 2006, ceased operations ~2015): Aurora built a raceway pond system in Karratha, Western Australia, targeting omega-3 EPA from Nannochloropsis for human nutrition. The biorefinery model involved EPA oil as primary product plus protein residue for aquafeed. The facility struggled with productivity — outdoor raceway ponds in Western Australia produced yields significantly below the TEA projections, which had been modelled on laboratory data. The cost of harvesting (centrifugation), combined with lower-than-projected productivity, meant the cost per kilogram of EPA was approximately twice the modelled cost. The protein co-product was insufficient to offset the primary product shortfall. Aurora raised over $100 million and produced product at pilot scale, but could not achieve cost parity with fish-oil-derived EPA and ceased operations.
The common thread: both failures involved biorefinery models where the primary product economics were marginal at best, and co-product revenues were projected but not contracted. When the primary product underperformed (due to price collapse or yield shortfall), there was no co-product revenue robust enough to sustain the operation. The lesson for investors: ask what happens to the economics when primary product yield is 70% of projection and price is 20% lower than assumed. If the answer is "the company fails," the biorefinery model is not de-risked — it is optimism with an extraction unit attached.
The capital requirement for a functional Chlorella lutein biorefinery — cultivation (photobioreactor or raceway), harvesting (centrifuge), cell disruption, solvent extraction for lutein, protein extraction equipment, and anaerobic digestion for residue — is realistically ₹3–8 crore for a pilot-scale facility producing meaningful commercial quantities (100–500 kg dry biomass/day). ₹2 crore will not fund the full cascade. Attempting to build a partial cascade will mean investing in infrastructure that cannot produce any of the three revenue streams reliably.
More fundamentally, a three-product cascade creates three sets of regulatory requirements (FSSAI novel food, pharma-grade lutein documentation, biogas producer registration), three sets of buyer relationships, and three sets of quality control systems. A 3-person team cannot manage this simultaneously.
The recommendation: Pick one product and prove it. Chlorella + lutein extraction is the strongest single-product starting point because: (a) lutein from algae commands $1,000–2,000/kg at pharmaceutical grade, (b) Chlorella is well-established in India with existing know-how, and (c) the extraction method (ethanol or SC-CO₂) is technically accessible at small scale. Use ₹1.5 crore to build a small-scale Chlorella cultivation system and lutein extraction pilot. Sell to one buyer. Prove the yield and quality. Then use that revenue and the credibility of an operating facility to raise the next round, which funds the protein extraction line as a genuine co-product addition — not as a simultaneous bet.
The biorefinery is the Year 3–5 state of this company. Not the Year 1 state. The startups that fail are those that try to build the full cascade before they have proven that any single product is viable at their scale and cost structure. The ones that succeed prove one product, then layer co-products as the primary product generates cash flow.